Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Low-dose Immunotherapy in dMMR/MSI Colorectal Cancer
NCT07523763Phase 2Active, not recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pembrolizumab in colorectal cancer (CRC), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Mar 2024; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07523763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523763.